Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene

Rong Li\textsuperscript{a}, Manisha Pradhan\textsuperscript{a}, Miao Xu\textsuperscript{a}, Amanda Baskfield\textsuperscript{a}, Atena Farkhondeh\textsuperscript{a}, Yu-Shan Cheng\textsuperscript{a}, Jeanette Beers\textsuperscript{b}, Jizhong Zou\textsuperscript{b}, Chengyu Liu\textsuperscript{c}, Matthew Might\textsuperscript{d}, Steven Rodems\textsuperscript{e}, Wei Zheng\textsuperscript{a,}\*\textsuperscript{*} \\
\textsuperscript{a}National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA \\
\textsuperscript{b}iPSC core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA \\
\textsuperscript{c}Transgenic Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA \\
\textsuperscript{d}University of Alabama at Birmingham, Birmingham, AL, USA \\
\textsuperscript{e}Retrophin, Inc., San Diego, CA, USA

Abstract

NGLY1 deficiency is a rare genetic disease caused by mutations in the NGLY1 gene that encodes N-glycanase 1. The disease phenotype in patient cells is unclear. A human induced pluripotent stem cell (iPSC) line was generated from skin dermal fibroblasts of a patient with NGLY1 deficiency that has compound heterozygous mutations of a p.Q208X variant (c.622C \(\rightarrow\) T) in exon 4 and a p.G310G variant (c.930C \(\rightarrow\) T) in exon 6 of the NGLY1 gene. This iPSC line offers a useful resource to study the disease pathophysiology and a cell-based model for drug development to treat NGLY1 deficiency.

Resource table

| Unique stem cell line identifier | TRNDi002-B |
|----------------------------------|------------|
| Alternative name(s) of stem cell line | HT519B |
| Institution                      | National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, Maryland, USA |
| Contact information of distributor | Dr. Wei Zheng, Wei.Zheng@nih.gov |
| Type of cell line                | iPSC |
| Origin                           | Human |

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/). 
\*Corresponding author at: National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, MSC: 3375, Bethesda, MD 20892, USA. wzeng@mail.nih.gov (W. Zheng).
### Resource utility

This hiPSC line is a useful tool for studies of disease phenotype, disease pathophysiology, and use as a cell-based disease model for drug development to treat patients with NGLY1 deficiency.

### Resource details

NGLY1 deficiency or NGLY1-congenital disorder of deglycosylation is a rare autosomal recessive disorder caused by mutations in the *NGLY1* gene, which encodes N-glycanase 1. It cleaves N-linked glycans from glycoproteins. Deficiency in N-glycanase 1 results in malfunctions in deglycosylation of N-glycosylated proteins. Because protein glycosylation and deglycosylation play an important role in post-translational modification of proteins, deficiency of this enzyme can cause protein misfolding and aggregation in the endoplasmic reticulum and cytosol, as well as proteasome dysfunction due to defective processing of Nrf1. The typical features of NGLY1 deficiency include developmental delay or intellectual disability of varying degrees, lack of tear production, elevated liver transaminases, and a complex movement disorder ([Lam et al., 1993](#); [Suzuki, 2016](#); [Tomlin et al., 2017](#)).

In this study, a human induced pluripotent stem cell line was established from skin fibroblasts of a 10-year-old male patient (GM25344, Coriell Institute) carrying compound heterozygous mutations of a p. Q208X variant (c.622C > T) in exon 4 and a p. G310G variant (c.930C > T) in exon 6 of the *NGLY1* gene (Table 1). This subject is also found to be heterozygous for a c.4060 A > T mutation (Thr1354Ser) in the CACNA1S gene based on the information released by Coriell Institute, which might represent one of the risk factors for increased susceptibility to malignant hyperthermia (MH) ([Beam et al., 2017](#)). To generate the iPSC cells, the non-integrating CytoTune-Sendai viral vector kit (A16517, Thermo Fisher

---

| Additional origin info | Age: 10-year-old |
|------------------------|------------------|
|                        | Sex: Male        |
|                        | Ethnicity: Caucasian |
| Cell Source            | Skin fibroblasts |
| Clonality              | Clonal           |
| Method of reprogramming| Integration-free Sendai viral vectors |
| Genetic modification   | NO               |
| Type of modification   | N/A              |
| Associated disease     | NGLY1 Deficiency |
| Gene/locus             | NGLY1^Q208X, NGLY1^G310G |
| Method of modification | N/A              |
| Name of transgene or resistance | N/A          |
| Inducible/constitutive system | N/A            |
| Date archived/stock date | 04-27-2018 |
| Cell line repository/bank | Human Pluripotent Stem Cell Registry [https://hpscreg.eu/cell-line/TRNDi002-B](https://hpscreg.eu/cell-line/TRNDi002-B) |
| Ethical approval       | NIGMS Informed Consent Form was obtained from patient at time of sample submission. Confidentiality Certificate: CC-GM-15-004 |

---

*Stem Cell Res. Author manuscript; available in PMC 2019 May 01.*
Scientific) containing OCT3/4, KLF4, SOX2 and C-MYC pluripotency transcription factors was employed to transduce the patient fibroblasts using the method described previously (Beers et al., 2015). The iPSC line named TRNDi002-B was generated from the patient fibroblasts. The mutations (c.622C > T and C.930C > T) of the NGLY1 gene described by Coriell Institute were confirmed in the TRNDi002-B iPSC line by Sanger sequencing of the PCR product harboring the single nucleotide variation (SNV) (Fig. 1D). The patient iPSC cells exhibited a classical embryonic stem cell morphology (Fig. 1A) and normal karyotype (46, XY), as confirmed by the G-banded karyotyping at passage 11 (Fig. 1C), expressed the major pluripotent protein markers of NANOG, SOX2, OCT4, SSEA4 and TRA-1-60 (Fig. 1A, B) evidenced by both immunofluorescence staining and flow cytometry analysis. Sendai virus vector (SeV) clearance was detected with reverse transcription polymerase chain reaction (RT-PCR) using SeV-specific primers, the vector disappeared by passage 15 (Fig. 1E). This iPSC line was not contaminated with mycoplasma (Supplementary Fig. S1) and were authenticated using STR DNA profiling analysis, which demonstrated matching genotypes at all 18 loci examined (information available with the authors). Furthermore, the pluripotency of this iPS cell line was confirmed by the teratoma formation experiment that exhibited its ability to differentiate into cells of all three germ layers (Ectoderm, neural tube; Mesoderm, cartilage; Endoderm, gut) in vivo (Fig. 1F).

**Materials and methods**

**Cell culture**

Patient skin fibroblasts were purchased from Coriell Cell Repositories (GM25344) and cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin in a humidified incubator with 5% CO₂ at 37 °C. Human iPS cells were cultured in StemFlex medium (Thermo Fisher) on Matrigel (Corning, 354277)-coated plates at 37 °C in humidified air with 5% CO₂ and 5% O₂. The cells were passaged with 0.5 mM Ethylenediaminetetraacetic acid (EDTA) at generally 1:6 ratio when they reach 80% confluency.

**Reprogramming of human skin fibroblasts**

Patient fibroblasts were reprogrammed into iPS cells using the non-integrating Sendai virus technology following the method described previously (Beers et al., 2015).

**Genome analysis**

The genome analysis of variants in NGLY1 was conducted through Applied StemCell (Milpitas, California, USA). Briefly, genomic DNA was extracted from hiPSC line TRNDi002-B using QuickExtract™ DNA Extraction Solution (Lucigen) followed by PCR amplification using MyTaq™ Red Mix (Bioline, Taunton, MA). Amplifications were carried out on T00 Thermal Cycler from Bio-Rad (#1861096) using the following program: 95 °C, 2 mins; 35 cycles of [95 °C, 15 s; 60 °C, 15 s; 72 °C, various length depending on size of amplicon], 72 °C 5 mins; 4 °C, indefinite. Genotyping of the compound heterozygous for a p. Q208X variant (c.622C > T) in exon 4 and a p.G310G variant (c.930C > T) in exon 6 of the NGLY1 gene were performed using Sanger sequencing analysis. The specific primers for gene amplification and sequencing are listed in Table 2.
Immunocytochemistry

For immunofluorescence staining, patient iPSCs were fixed in 4% paraformaldehyde for 15 mins, rinsed with DPBS, and permeabilized with 0.3% Triton X-100 in DPBS for 15 mins. The cells were incubated with the Image-iT™ FX signal enhancer (ThermoFisher Scientific) for 40 mins at room temperature in a humidified environment and then followed by incubation individually with primary antibodies including SOX2, OCT4, NANOG, SSEA4 and TRA-1-60, diluted in the Image-iT™ FX signal enhancer blocking buffer, for overnight at 4 °C. After washing with DPBS, a corresponding secondary antibody conjugated with Alexa Fluor 488 or Alex Fluor 594 was added to the cells and incubated for 1 h at room temperature (Antibodies used are listed in Table 2). Cells were then stained with Hoechst 33342 for 15 mins after a wash and imaged using an INCell Analyzer 2200 imaging system (GE Healthcare) with 20× objective lens and Texas Red, FITC and DAPI filter sets.

Flow cytometry analysis

The iPSCs were harvested using TrypLE Express Enzyme (ThermoFisher Scientific). Cells were fixed with 4% paraformaldehyde for 10 mins at room temperature and then washed with DPBS. Before fluorescence-activated cell sorting analysis, cells were permeabilized with 0.2% Tween-20 in DPBS for 10 mins at room temperature and stained with fluorophore conjugated antibodies for 1 h at 4 °C on a shaker (Antibodies used are listed in Table 2). Cells were then analyzed on a BD Accuri™ C6 FlowCytometry system (BD Biosciences).

G-banding karyotype

The G-banding karyotype analysis was conducted at WiCell Research Institute (Madison, WI, USA). A total of 20 randomly selected metaphases were analyzed by G-banding for each cell line.

Short tandem repeat (STR) analysis

Patient fibroblasts and derived iPSC lines were sent to the Johns Hopkins University Genetic Resources Core Facility for STR DNA profile analysis using a Promega PowerPlex 18D Kit. The PCR product was electrophoresed on an ABI Prism® 3730x1 Genetic Analyzer and data was analyzed using GeneMapper® v 4.0 software (Applied Biosystems).

Mycoplasma detection

Mycoplasma testing was performed and analyzed using the Lonza MycoAlert kit following the instructions from the company. Ratio B/A > 1.2 indicates mycoplasma positive; 0.9–1.2 Result indicates ambiguous; < 0.9 indicates mycoplasma negative.

Sendai virus detection

Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen). Human fibroblasts (GM05659, Coriell Institute) after transfection with Sendai virus for 4 days was used as the positive control. 1 μg of RNA was reverse transcribed into cDNA with Superscript™ III First-Strand Synthesis SuperMix kit and PCR was performed using Platinum II Hot-Start PCR Master Mix (ThermoFisher Scientific) and the amplifications were carried out using the following program: 94 °C, 2 mins; 30 cycles of 94 °C, 15 s, 60 °C, 15 s and 68 °C, 15
s on Mastercycler pro S (Eppendorf) with the primers listed in Table 2. The products were then loaded to the E-Gel® 1.2% with SYBR Safe™ gel, and imaged by G: Box Chemi-XX6 gel doc system (Syngene, Frederick, MD).

**Teratoma formation assay**

Patient iPSCs cultured in 6-well plates were dissociated with DPBS containing 0.5 mM EDTA, and approximately 1 × 10^7 dissociated cells were resuspended in 400 μl culture medium supplied with 25mM HEPES (pH 7.4) and stored on ice. Then, 50% volume (200 μl) of cold Matrigel (Corning, 354277) was added and mixed with the cells. The mixture was injected subcutaneously into NSG mice (JAX No. 005557) at 150 μl per injection site. Visible tumors were removed 6–8 weeks post injection, and were immediately fixed in 10% Neutral Buffered Formalin. The fixed tumors were embedded in paraffin and stained with hematoxylin and eosin.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.scr.2018.101362.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgement**

We would like to thank Dr. Zu-xi Yu of the pathology Core of National Heart, Lung and Blood Institute, National Institutes of Health for sectioning and staining the teratoma. We also would like to thank Tobie Lee and Kelli Wilson of the Research Services Section at National Center for Advancing Translational Sciences for coordinating the STR DNA analysis and mycoplasma testing service. We would like to acknowledge Beth Aselage from Retrophin and Carrie Ostrea from NGLY1.org for helpful discussions. This work was supported by the Therapeutics for Rare and Neglected Diseases Program, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, under a CRADA collaboration between NCATS, NGLY1.org, and Retrophin.

**References**

Beam TA, Loudermilk EF, Kisor DF, 2017. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia. Physiol. Genomics 49, 81–87. [PubMed: 28011884]

Beers J, Linask KL, Chen JA, Siniscalchi LI, Lin Y, Zheng W, Rao M, Chen G, 2015. A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. Sci. Rep. 5, 11319. [PubMed: 26066579]

Lam C, Wolfe L, Need A, Shashi V, Emns G, 1993. NGLY1-related congenital disorder of deglycosylation. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (Eds.), GeneReviews((R)), Seattle (WA).

Suzuki T, 2016. Catabolism of N-glycoproteins in mammalian cells: molecular mechanisms and genetic disorders related to the processes. Mol. Asp. Med. 51, 89–103.

Tomlin FM, Gerling-Driessen UIM, Liu YC, Flynn RA, Vangala JR, Lentz CS, Clauder-Muenster S, Jakob P, Mueller WF, Ordonez-Rueda D, Paulsen M, Matsui N, Foley D, Rafalko A, Suzuki T, Bogyo M, Steinmetz LM, Radhakrishnan SK, Bertozzi CR, 2017. Inhibition of NGLY1 inactivates the transcription factor Nrf1 and potentiates proteasome inhibitor cytotoxicity. ACS Cent. Sci. 3, 1143–1155. [PubMed: 29202016]
Fig. 1. Characterization of TRNDi002-B iPSC line.
A) Left: Phase contrast imaging of TRNDi002-B colonies grown on Matrigel at passage 10. Right: Representative immunofluorescent micrographs of iPSCs positive for stem cell markers: SOX2, OCT4, TRA-1-60, NANOG, and SSEA4. Nucleus is labelled with Hoechst (in blue).
B) Flow cytometry analysis of pluripotency protein markers: TRA-1-60, NANOG and SSEA4.
C) Cytogenetic analysis showing a normal karyotype (46, XY).
D) Detection of compound heterozygous of a p.Q208X variant (c.622C > T) in exon 4 and a p.G310G (c.930C > T) in exon 6 of the NGLY1 gene.
E) RT-PCR verification of the clearance of...
Sendai virus from the reprogrammed cells. Sendai virus vector transduced fibroblasts was used as positive control. F) Pathological analysis of a teratoma from TRNDi002-B iPSC, showing a normal ectodermal, endodermal and mesodermal differentiation.
Table 1

| Classification          | Test                        | Result                                                                 | Data                        |
|-------------------------|-----------------------------|------------------------------------------------------------------------|-----------------------------|
| Morphology              | Photography                 | Normal                                                                  | Fig. 1 Panel A              |
| Phenotype               | Immunocytochemistry         | SOX2, OCT4, NANOG, SSEA-4, TRA-1-60                                     | Fig. 1 Panel A              |
|                         | Flow cytometry              | TRA-1-60 (87.5%); NANOG (92.1%); SSEA-4 (99.9%)                        | Fig. 1 Panel B              |
| Genotype                | Karyotype (G-banding) and resolution | 46XY Resolution: 350–400                                                | Fig. 1 Panel C              |
| Identity                | Microsatellite PCR (mPCR) OR | Not performed                                                           | N/A                         |
|                         | STR analysis                | 18 sites tested, all sites matched                                      | Available with the authors  |
| Mutation analysis (IF APPLICABLE) | Sequencing                  | Compound heterozygous mutation of NGLY1                                | Fig. 1 Panel D              |
|                         | Southern Blot OR WGS        | N/A                                                                     | N/A                         |
| Microbiology and virology | Mycoplasma                  | Mycoplasma testing by luminescence. Negative                           | Supplementary Fig. S1       |
| Differentiation potential | Teratoma formation          | Teratoma with three germ layers formation. Ectoderm (neural tube); Mesoderm (cartilage); Endoderm (gut) | Fig. 1 Panel F              |
| Donor screening (OPTIONAL) | HIV 1 + 2 Hepatitis B, Hepatitis C | N/A                                                                    | N/A                         |
| Genotype additional info (OPTIONAL) | Blood group genotyping      | N/A                                                                    | N/A                         |
|                         | HLA tissue typing           | N/A                                                                    | N/A                         |
Reagents details.

### Table 2

**Antibodies used for immunocytochemistry/flow-cytometry**

| Antibody                      | Dilution | Company Cat # and RRID                                      |
|-------------------------------|----------|------------------------------------------------------------|
| Pluripotency markers          |          |                                                            |
| Mouse anti-SOX2               | 1:50     | R & D systems, Cat# MAB2018, RRID: AB_358009                |
| Rabbit anti-NANOG             | 1:400    | Cell signaling, Cat# 4903, RRID: AB_10559205                |
| Rabbit anti-OCT4              | 1:400    | Thermo Fisher, Cat# A13998, RRID: AB_2534182                |
| Mouse anti-SSEA4              | 1:1000   | Cell signaling, Cat# 4755, RRID: AB_1264259                |
| Mouse anti-TRA-1-60- Alexa Fluor 488 | 1:10   | BD Biosciences, Cat# 560173, RRID: AB_1645379               |
| Secondary antibodies         |          |                                                            |
| Donkey anti-Mouse IgG (Alexa Fluor 488) | 1:400 | Thermo Fischer, Cat# A21202, RRID: AB_141607               |
| Donkey anti-Rabbit IgG (Alexa Fluor 594) | 1:400 | Thermo Fischer, Cat# A21207, RRID: AB_141637               |
| Flow cytometry antibodies     |          |                                                            |
| Anti-Tra-1-60-DyLight 488     | 1:50     | Thermo Fischer, Cat# MA1–023-D488X, RRID: AB_2536700       |
| Anti-Nanog-Alexa Fluor 488    | 1:50     | Millipore, Cat# FCABS352A4, RRID: AB_10807973              |
| anti-SSEA-4-Alexa Fluor 488   | 1:50     | Thermo Fischer, Cat# 53–8843-41, RRID: AB_10597752         |
| Mouse-IgM-DyLight 488         | 1:50     | Thermo Fischer, Cat# MA1–194-D488, RRID: AB_2536969        |
| Rabbit IgG-Alexa Fluor 488    | 1:50     | Cell Signaling, Cat# 4340S, RRID: AB_10694568              |
| Mouse IgG3-FITC               | 1:50     | Thermo Fischer, Cat# 11–4742-42, RRID: AB_2043894          |

**Primers**

| Target                     | Forward/reverse primer (5’–3’) |
|----------------------------|--------------------------------|
| Sev specific primers (RT-PCR) | GGA TCA CTA GGT GAT ATC GAG C/ACC AGA CAA GAG TTT AAG AGA TAT GTA TC |
| Sev specific primers (RT-PCR) | ATG CAC CGC TAC GAC GTG AGC GC/ACC TTG ACA ATC CTG ATG TGG |
| Sev specific primers (RT-PCR) | TTC CTG CAT GCC AGA GGA GCC C/AAT GTA TCG AAG GTG CTC AA |
| Sev specific primers (RT-PCR) | TAA CTG ACT AGC AGG CTT GTC C/TCC ACA TAC AGT CCT GGA TGA TGA TGG |
| Sev specific primers (RT-PCR) | ATG CAC CGC TAC GAC GTG AGC GC/ACC TTG ACA ATC CTG ATG TGG |
| Sev specific primers (RT-PCR) | GGA GCG AGA TCC CTC CAA AAT/GGC TGT TGT CAT ACT TCT CAT GTG |
| Targeted mutation analysis (PCR) | CCA TGC AGT CAC AAT GGC TGT TGT C/TCC ACA TAC AGT CCT GGA TGA TGA TGG |
| Targeted mutation analysis (PCR) | ATG CAC CGC TAC GAC GTG AGC GC/ACC TTG ACA ATC CTG ATG TGG |
| Targeted mutation analysis (PCR) | CCA TGC AGT CAC AAT GGC TGT TGT CAT ACT TCT CAT GTG |
| Targeted mutation analysis (PCR) | CCA TGC AGT CAC AAT GGC TGT TGT CAT ACT TCT CAT GTG |